A Randomised, Single-blind, Single Center, Placebo-controlled, Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD7503 Following Multiple Subcutaneous Dose Administration in Healthy Japanese Participants
Latest Information Update: 06 May 2024
At a glance
- Drugs ION 455 (Primary)
- Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
- Focus Adverse reactions
- Sponsors AstraZeneca
Most Recent Events
- 29 Apr 2024 Status changed from active, no longer recruiting to completed.
- 22 Dec 2023 Planned End Date changed from 10 Apr 2024 to 20 Mar 2024.
- 22 Dec 2023 Planned primary completion date changed from 10 Apr 2024 to 20 Mar 2024.